A green approach to dual-drug nanoformulations with targeting and synergistic effects for cancer therapy

References

• Ahmed F, Pakunlu RI, Brannan A, et al. (2006). Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. J Control Release 116:150–8
   PubMed Web of Science ®Google Scholar
• Al-Lazikani B, Banerji U, Workman P. (2012). Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 30:679–91
   PubMed Web of Science ®Google Scholar
• Anderson RGW, Kamen BA, Rothberg KG, Lacey SW. (1992). Potocytosis: sequestration and transport of small molecules by caveolae. Science 255:410–11
   PubMed Web of Science ®Google Scholar
• Aryal S, Hu CMJ, Zhang L. (2010). Combinatorial drug conjugation enables nanoparticle dual-drug delivery. Small 6:1442–8
   PubMed Web of Science ®Google Scholar
• Ashley CE, Carnes EC, Phillips GK, et al. (2011). The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater 10:389–97
   PubMed Web of Science ®Google Scholar
• Bahadur RKC, Xu P. (2012). Multicompartment intracellular self-expanding nanogel for targeted delivery of drug cocktail. Adv Mater Weinheim 24:6479–83
   PubMed Web of Science ®Google Scholar
• Barua S, Mitragotri S. (2013). Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticles. ACS Nano 7:9558–70
   PubMed Web of Science ®Google Scholar
• Barua S, Yoo JW, Kolhar P, et al. (2013). Particle shape enhances specificity of antibody-displaying nanoparticles. Proc Natl Acad Sci USA 110:3270–5
   PubMed Web of Science ®Google Scholar
• Batist G, Gelmon KA, Chi KN, et al. (2009). Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res 15:692–700
   PubMed Web of Science ®Google Scholar
• Calabro F, Lorusso V, Rosati G, et al. (2009). Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer 115:2652–9
   PubMed Web of Science ®Google Scholar
• Chabner BA, Roberts TG. (2005). Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 5:65–72
   PubMed Web of Science ®Google Scholar
• Champion JA, Katare YK, Mitragotri S. (2007). Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release 121:3–9
   PubMed Web of Science ®Google Scholar
• Champion JA, Mitragotri S. (2006). Role of target geometry in phagocytosis. Proc Natl Acad Sci USA 103:4930–4
   PubMed Web of Science ®Google Scholar
• Chen AM, Zhang M, Wei D, et al. (2009). Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 5:2673–7
   PubMed Web of Science ®Google Scholar
• Chen F, Zhao Y, Pan Y, et al. (2015). Synergistically enhanced therapeutic effect of a carrier-free HCPT/DOX nanodrug on breast cancer cells through improved cellular drug accumulation. Mol Pharm 12:2237–44
   PubMed Web of Science ®Google Scholar
• Choi CHJ, Alabi CA, Webster P, Davis ME. (2010). Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci USA 107:1235–40
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55
   PubMedGoogle Scholar
• Das M, Mardyani S, Chan WCW, Kumacheva E. (2006). Biofunctionalized pH-responsive microgels for cancer cell targeting: rational design. Adv Mater 18:80–3
   Web of Science ®Google Scholar
• Devita VT Jr., Young RC, Canellos GP. (1975). Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 35:98–110
   PubMed Web of Science ®Google Scholar
• Dilnawaz F, Singh A, Mohanty C, Sahoo SK. (2010). Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 31:3694–706
   PubMed Web of Science ®Google Scholar
• Duthie SJ. (2001). Folic-acid-mediated inhibition of human colon-cancer cell growth. Nutrition 17:736–7
   PubMed Web of Science ®Google Scholar
• Gottesman MM. (2002). Mechanisms of cancer drug resistance. Annu Rev Med 53:615–27
   PubMed Web of Science ®Google Scholar
• Gratton SEA, Ropp PA, Pohlhaus PD, et al. (2008). The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 105:11613–18
   PubMed Web of Science ®Google Scholar
• Guo X, Shi C, Wang J, et al. (2013). pH-triggered intracellular release from actively targeting polymer micelles. Biomaterials 34:4544–54
   PubMed Web of Science ®Google Scholar
• Holme MN, Fedotenko IA, Abegg D, et al. (2012). Shear-stress sensitive lenticular vesicles for targeted drug delivery. Nat Nanotechnol 7:536–43
   PubMed Web of Science ®Google Scholar
• Hong MH, Zhu SJ, Jiang YY, et al. (2009). Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J Control Release 133:96–102
   PubMed Web of Science ®Google Scholar
• Huang P, Wang D, Su Y, et al. (2014). Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug–drug conjugate for cancer therapy. J Am Chem Soc 136:11748–56
   PubMed Web of Science ®Google Scholar
• Jia J, Zhu F, Ma X, et al. (2009). Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8:111–28
   PubMed Web of Science ®Google Scholar
• Jia M, Li Y, Yang X, et al. (2014). Development of both methotrexate and mitomycin C loaded PEGylated chitosan nanoparticles for targeted drug codelivery and synergistic anticancer effect. ACS Appl Mater Interfaces 6:11413–23
   PubMed Web of Science ®Google Scholar
• Kocbek P, Obermajer N, Cegnar M, et al. (2007). Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 120:18–26
   PubMed Web of Science ®Google Scholar
• Kolishetti N, Dhar S, Valencia PM, et al. (2010). Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci USA 107:17939–44
   PubMed Web of Science ®Google Scholar
• Lammers T, Subr V, Ulbrich K, et al. (2009). Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 30:3466–75
   PubMed Web of Science ®Google Scholar
• Lehar J, Krueger AS, Avery W, et al. (2009). Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 27:659–U116
   PubMed Web of Science ®Google Scholar
• Li C, Wallace S. (2008). Polymer–drug conjugates: recent development in clinical oncology. Adv Drug Deliv Rev 60:886–98
   PubMed Web of Science ®Google Scholar
• Liao L, Liu J, Dreaden EC, et al. (2014). A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. J Am Chem Soc 136:5896–9
   PubMed Web of Science ®Google Scholar
• Lorusso PM, Canetta R, Wagner JA, et al. (2012). Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an Institute of Medicine Workshop. Clin Cancer Res 18:6101–9
   PubMed Web of Science ®Google Scholar
• Ma L, Kohli M, Smith A. (2013). Nanoparticles for combination drug therapy. ACS Nano 7:9518–25
   PubMed Web of Science ®Google Scholar
• Markovsky E, Baabur-Cohen H, Satchi-Fainaro R. (2014). Anticancer polymeric nanomedicine bearing synergistic drug combination is superior to a mixture of individually-conjugated drugs. J Control Release 187:145–57
   PubMed Web of Science ®Google Scholar
• Martello LA, Mcdaid HM, Regl DL, et al. (2000). Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 6:1978–87
   PubMed Web of Science ®Google Scholar
• Mcdaid HM, Johnston PG. (1999). Synergistic interaction between paclitaxel and 8-chloro-adenosine 3′,5′-monophosphate in human ovarian carcinoma cell lines. Clin Cancer Res 5:215–20
   PubMed Web of Science ®Google Scholar
• Meng H, Liong M, Xia T, et al. (2010). Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 4:4539–50
   PubMed Web of Science ®Google Scholar
• Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. (2009). Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev 61:26–33
   PubMed Web of Science ®Google Scholar
• Park J, Wrzesinski SH, Stern E, et al. (2012). Combination delivery of TGF-beta inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumor immunotherapy. Nat Mater 11:895–905
   PubMed Web of Science ®Google Scholar
• Patil Y, Sadhukha T, Ma L, Panyam J. (2009). Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 136:21–9
   PubMed Web of Science ®Google Scholar
• Patil YB, Swaminathan SK, Sadhukha T, et al. (2010). The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31:358–65
   PubMed Web of Science ®Google Scholar
• Rosenholm JM, Peuhu E, Bate-Eya LT, et al. (2010). Cancer-cell-specific induction of apoptosis using mesoporous silica nanoparticles as drug-delivery vectors. Small 6:1234–41
   PubMed Web of Science ®Google Scholar
• Sahay G, Alakhova DY, Kabanov AV. (2010). Endocytosis of nanomedicines. J Control Release 145:182–95
   PubMed Web of Science ®Google Scholar
• Sengupta S, Eavarone D, Capila I, et al. (2005). Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436:568–72
   PubMed Web of Science ®Google Scholar
• Soma CE, Dubernet C, Bentolila D, et al. (2000). Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 21:1–7
   PubMed Web of Science ®Google Scholar
• Song J, Zhou J, Duan H. (2012). Self-assembled plasmonic vesicles of SERS-encoded amphiphilic gold nanoparticles for cancer cell targeting and traceable intracellular drug delivery. J Am Chem Soc 134:13458–69
   PubMed Web of Science ®Google Scholar
• Sun CY, Shen S, Xu CF, et al. (2015). Tumor acidity-sensitive polymeric vector for active targeted siRNA delivery. J Am Chem Soc 137:15217–24
   PubMed Web of Science ®Google Scholar
• Tian Y, Shi C, Sun Y, et al. (2015). Designing micellar nanocarriers with improved drug loading and stability based on solubility parameter. Mol Pharm 12:816–25
   PubMed Web of Science ®Google Scholar
• Vacha R, Martinez-Veracoechea FJ, Frenkel D. (2011). Receptor-mediated endocytosis of nanoparticles of various shapes. Nano Lett 11:5391–5
   PubMed Web of Science ®Google Scholar
• Wang Y, Gao S, Ye WH, et al. (2006). Co-delivery of drugs and DNA from cationic core–shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 5:791–6
   PubMed Web of Science ®Google Scholar
• Wang YS, Chen HL, Liu YY, et al. (2013). pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma. Biomaterials 34:7181–90
   PubMed Web of Science ®Google Scholar
• Wang Z, Ho PC. (2010). A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities. Biomaterials 31:7115–23
   PubMed Web of Science ®Google Scholar
• Weitman SD, Lark RH, Coney LR, et al. (1992). Distribution of the folate receptor GP38 in normal and malignant-cell lines and tissues. Cancer Res 52:3396–401
   PubMed Web of Science ®Google Scholar
• Wu W, Li RT, Bian XC, et al. (2009). Covalently combining carbon nanotubes with anticancer agent: preparation and antitumor activity. ACS Nano 3:2740–50
   PubMed Web of Science ®Google Scholar
• Yan Y, Bjoernmalm M, Caruso F. (2013). Particle carriers for combating multidrug-resistant cancer. ACS Nano 7:9512–17
   PubMed Web of Science ®Google Scholar
• Yang X, Wu S, Li Y, et al. (2015). Integration of an anti-tumor drug into nanocrystalline assemblies for sustained drug release. Chem Sci 6:1650–4
   PubMed Web of Science ®Google Scholar
• Zhao YY, Chen F, Pan YM, et al. (2015). Nanodrug formed by coassembly of dual anticancer drugs to inhibit cancer cell drug resistance. ACS Appl Mater Interfaces 7:19295–305
   PubMed Web of Science ®Google Scholar
• Zhou MJ, Zhang XJ, Yang YL, et al. (2013). Carrier-free functionalized multidrug nanorods for synergistic cancer therapy. Biomaterials 34:8960–7
   PubMed Web of Science ®Google Scholar